In a significant strategic move, Danish pharmaceutical giant Novo Nordisk has announced a substantial price reduction for its popular weight-loss medication, Wegovy, in the Indian market. The decision comes as the company prepares for intensified competition ahead of its patent exclusivity ending in March.
Sharp Price Drop for Obesity Treatment
The monthly cost of the starting dose of Wegovy has been reduced by 37%, dropping from the previous price of ₹17,345 to a new, more accessible price of ₹10,850. This price revision applies across the various dosage strengths of the once-weekly injection. The cost per weekly dose is now ₹2,712, a significant decrease from the earlier ₹4,336.
The revised pricing structure for the different doses is now as follows: the 0.5 mg and 1 mg doses will be available for a monthly cost of ₹13,850, while the higher 1.7 mg and 2.4 mg doses will be priced at ₹16,400 each. Wegovy, which contains the active ingredient semaglutide, was initially launched in India in June 2025 and is administered via a pen device.
Race Against Time and Competition
This aggressive pricing strategy is a direct response to the impending loss of patent protection for the drug. In March, Novo Nordisk will lose its market exclusivity, opening the doors for several major Indian generic drug manufacturers to introduce their own, lower-cost versions of the medication. Companies like Dr. Reddy's, Sun Pharma, Mankind Pharma, and Natco are poised to enter the market, which will likely drive prices down further.
Vikrant Shrotriya, the Managing Director of Novo Nordisk India, stated in an official release, "Obesity is a serious concern for India and this price revision underlines our mission to provide quality obesity treatment to Indians which is effective, safe, convenient and can be sustained in their daily lives."
A Crowded Battlefield for Weight-Loss Drugs
Novo Nordisk's challenges are not limited to future generic competition. The company is already engaged in a fierce battle with rival Eli Lilly, which has captured a significant portion of the Indian weight-loss drug market with its product, Mounjaro. Data from the pharmaceutical intelligence platform Pharmarack reveals a stark contrast in sales performance. As of October, Mounjaro's monthly sales were nearly ten times greater than those of Wegovy.
Launched in India in late March 2025, Mounjaro quickly rose to become the country's top-selling brand in its category by October, achieving sales of ₹100 crore. Its pricing starts at ₹14,000 per month for the 2.5 mg dose and can go up to ₹27,500 for the highest 15 mg dose.
In a parallel move to expand its market reach, Novo Nordisk announced an exclusive partnership with Pune-based Emcure Pharmaceuticals on Monday. This collaboration will see Emcure distribute the weight-loss drug under the brand name Poviztra. Although the specific price and launch date for Poviztra were not disclosed, the companies have committed to being "very competitive" in their pricing, aiming to penetrate markets that were previously difficult for Novo Nordisk to access directly.
This pre-emptive price cut by Novo Nordisk is expected to put considerable pressure on domestic generic manufacturers, who will now have to recalibrate their own cost structures to remain competitive when they launch their products later this year. This tactic mirrors strategies seen in markets like the United States, where drug prices often fall in anticipation of new branded or generic competition, even before a product's market exclusivity officially ends.
